Overview

Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults

Status:
Completed

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the pharmacokinetics (PK) of HCV-796 in subjects with chronic hepatic impairment and in matched healthy adults.

Phase:

Phase 1

Details

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Collaborator:

ViroPharma